Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671
June 20, 2025 19:30 ET | Source: Structure Therapeutics Inc. SAN FRANCISCO,…
Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update
June 19, 2025 01:00 ET | Source: Addex Therapeutics Strong cash position…
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split
June 18, 2025 16:30 ET | Source: Cellectar Biosciences, Inc. FLORHAM PARK,…
Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025
June 18, 2025 01:00 ET | Source: Addex Therapeutics Geneva, Switzerland, June…
Winner of the Biotherapies and Bioproduction call for projects under the France 2030 plan, EVerZom receives 3 million in government funding to industrialize its exosome bioproduction technology
Winner of the “Biotherapies and Bioproduction” call for projects under the France…
AVEROA receives European marketing authorization for XOANACYL, an Oral Therapy for Chronic Kidney Disease (CKD)
XOANACYL is an oral therapy designed to address critical challenges in CKD,…
EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL
ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage…
ArkBio’s New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA
SHANGHAI, June 16, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio")…
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 13, 2025 16:01 ET | Source: Nurix Therapeutics, Inc. SAN FRANCISCO,…
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
June 13, 2025 09:00 ET | Source: RAPT Therapeutics, Inc. SOUTH SAN…